Levetiracetam Solution
Product Images NDC 62135-548

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Levetiracetam Solution (NDC 62135-548). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Chartwell Rx, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

"levetiracetam Solution (100mg/mL)

Levetiracetam Oral Solution, USP 100 mg/mL label for a 473 mL (16 fl oz) bottle by Chartwell Rx, LLC. The label includes pharmacist dispensing instructions, medication guide notice, storage and warning information, a barcode, and states the product is Rx only. It is made in the USA.*

FDA Label Image

"image Description" (Levetiracetam Chemical Structure)

Chemical structure of levetiracetam, showing the molecular arrangement with a pyrrolidine ring and functional groups, consistent with the active ingredient in the LEVETIRACETAM solution oral dosage form.*

FDA Label Image

"image Description" (Levetiracetam Figure 1)

A bar graph comparing the percentage of patients across three groups: Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 3000 mg/day. The y-axis represents the percentage of patients, with Levetiracetam 3000 mg/day showing the highest percentage, followed by 1000 mg/day, and the placebo group the lowest.*

FDA Label Image

"image Description" (Levetiracetam Figure 3)

Bar chart comparing the percentage of patients responding to placebo and Levetiracetam 3000 mg/day treatments. The chart shows approximately 14.4% response for placebo and 39.4% for Levetiracetam 3000 mg/day among the sample sizes indicated.*

FDA Label Image

"image Description" (Levetiracetam Figure 4)

A bar chart comparing the percentage of patients for Placebo (N=97) and Levetiracetam (N=101). The chart shows 19.6% for Placebo and 44.6% for Levetiracetam, with the y-axis representing the percentage of patients from 0% to 45%.*

FDA Label Image

"image Description" (Levetiracetam Figure 5)

A bar graph comparing the percentage of patients in two groups: placebo and levetiracetam. The placebo group shows 19.6% of patients, while the levetiracetam group shows 43.1%. The chart includes sample sizes (Placebo: N=51, Levetiracetam: N=58). An asterisk marks the levetiracetam bar, indicating statistical significance or emphasis.*

FDA Label Image

"image Description" (Levetiracetam Figure 6)

A bar chart comparing the percentage of patients in two groups, Placebo and Levetiracetam, with Levetiracetam showing 72.2% and Placebo 45.2%. The chart likely illustrates patient response or outcome differences between treatments.*

FDA Label Image

"image Description" (Levetiracetam Figure 7)

A bar chart comparing the percentage of patients in three groups: Placebo (6.3%, N=111), Levetiracetam 100 mg/day (20.8%, N=106), and Levetiracetam 200 mg/day (35.2%). The chart shows increasing percentages of patients with higher Levetiracetam doses.*

FDA Label Image

"image Description" (Levetiracetam Formula 1)

A mathematical formula for calculating the daily dose based on patient weight, expressed as total daily dose (mL/day) equals the product of daily dose (mg/kg/day) and patient weight (kg) divided by 100 mg/mL concentration.*

FDA Label Image

"image Description" (Levetiracetam Formula 2)

A formula displayed as a mathematical equation calculating creatinine clearance (CLcr), factoring in age, weight, serum creatinine level, and a correction factor for female patients. The variables include age in years, weight in kilograms, serum creatinine in mg/dL, and an adjustment multiplier of 0.85 for females.*

FDA Label Image

"image Description" (Levetiracetam Formula 3)

Mathematical formula depicting the calculation of creatinine clearance (CLcr) based on CLcr in mL/min normalized to body surface area (BSA) in m2, scaled by a factor of 1.73 m2. This formula is commonly used in pharmacokinetics and renal function assessment.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.